Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
Saved in:
| Title: | Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report. |
|---|---|
| Authors: | Velthaus JL; Department of Hematology, Oncology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, j.velthaus@uke.de., Iglauer P; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Simon R; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Bokemeyer C; Department of Hematology, Oncology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Bannas P; Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany., Beumer N; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Division of Applied Bioinformatics (B330), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany., Imbusch CD; Division of Applied Bioinformatics (B330), German Cancer Research Center (DKFZ), Heidelberg, Germany., Goekkurt E; Department of Hematology, Oncology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Hematology-Oncology Practice Hamburg (HOPE), Hamburg, Germany., Loges S; Department of Hematology, Oncology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum, University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. |
| Source: | Oncology research and treatment [Oncol Res Treat] 2021; Vol. 44 (9), pp. 495-502. Date of Electronic Publication: 2021 Jul 28. |
| Publication Type: | Case Reports; Journal Article |
| Journal Info: | Publisher: S. Karger Country of Publication: Switzerland NLM ID: 101627692 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2296-5262 (Electronic) Linking ISSN: 22965270 NLM ISO Abbreviation: Oncol Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2296-5262 |
|---|---|
| DOI: | 10.1159/000517616 |
